Evidence-based clinical decision making - Glycemic control and hemoglobinopathy: When A1C may not be reliable

Diabetes Spectrum

Volumn 21, Issue 1, 2008, Pages 46-49

  Smaldone, Arlene ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HASHIMOTO DISEASE; HEMOGLOBIN DETERMINATION; HEMOGLOBINOPATHY; HOME MONITORING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 40449121830     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.21.1.46     Document Type: Article

References (33)

1. American Diabetes Association: Standards of medical care in diabetes - 2007 [Position Statement]. Diabetes Care 30 (Suppl. 1):S4-S41, 2007
2. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
4. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48:436-472, 2002
5. Bry L, Chen PC, Sacks DB: Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 47:153-163, 2001
6. University of Iowa Hospital and Clinics: Sickle cell trait [article online], 1993. Available online from http://www.uihealthcare.com/topics/ medicaldepartments/pediatrics/ sicklecell/indes.html. Accessed 7 April 2007
7. Schneider RG, Hightower B, Hosty TS, Ryder H, Tomlin G, Atkins R, Brimhall B, Jones RT: Abnormal hemoglobins in a quarter million people. Blood 48:629-637, 1976
8. Rowley PT: Parental receptivity to neonatal sickle trait identification. Pediatrics 83:891-893, 1989
9. New York State Department of Health: Newborn screening program [article online]. Available online from http://www.wadsworth.org/newborn/scell/scell.htm. Accessed 7 April 2007
10. Tran H, Silva D, Petrovsky N: Case study: potential pitfalls of using hemoglobin A1c as the sole measure of glycemic control. Clin Diabetes 22:141-143, 2004
11. 1c determination and hemoglobinopathies: problems and strategies. Ann Biol Clin (Paris) 58:425-429, 2000
12. 1c. JAMA 295:1688-1697, 2006
13. Washington University Natural Sciences Learning Center: The molecular biology of sickle cell anemia [article online]. Available online from http://www.nslc.wustl.edu/ sicklecell/part2/molecular.html. Accessed 14 August 2007
14. (1c) measurement. Diabetes Care 23:1197-1198, 2000
15. Kosecki SM, Rodgers PT, Adams MB: Glycemic monitoring in diabetics with sickle cell plus beta-thalassemia hemoglobinopathy. Ann Pharmacother 39:1557-1560, 2005
16. 1c levels in a poorly controlled diabetic. Postgrad Med J 79:418, 421, 2003
17. Schnedl WJ, Trinker M, Lipp RW: HbA1c determination in patients with hemoglobinopathies. Diabetes Care 22:368-369, 1999
18. 1c. Clin Diabetes 25:43-49, 2007
19. Mendlovic DB, Whitehouse FW, Foreback CC: The why and wherefore of fructosamine. Henry Ford Hosp Med J 40:149-151, 1992
20. 1c by an immunoassay method. Diabetes Care 21:983-986, 1998
21. Weykamp CW, Penders TJ, Muskiet FA, van der Slik W: Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 39:1717-1723, 1993
22. Dafallah AA, Eskandarani H, Rehaimi A, al-Ali AK, Elbashir AM, Saba R: Fructosamine in HbS and G6PD-deficient Saudi Arabs in the Eastern Province of Saudi Arabia. Br J Biomed Sci 51:332-335, 1994
23. Cefalu WT, Wang ZQ, Redmon E, Bell-Farrow AD, McBride D, King T: Clinical validity of a self-test fructosamine in outpatient diabetic management. Diabetes Technol Ther 1:435-441, 1999
24. 1c determination methods in patients with hemoglobinopathies. Diabetes Care 23:339-344, 2000
25. Allgrove J, Cockrill BL: Fructosamine or glycated haemoglobin as a measure of diabetic control? Arch Dis Child 63:418-422, 1988
26. Sobel DO, Abbassi V: Use of fructosamine test in diabetic children. Diabetes Care 14:578-583, 1991
27. Negoro H, Morley JE, Rosenthal MJ: Utility of serum fructosamine as a measure of glycemia in young and old diabetic and non-diabetic subjects. Am J Med 85:360-364, 1988
28. Baker JR, Metcalf PA, Holdaway IM, Johnson RN: Serum fructosamine concentration as measure of blood glucose control in type I (insulin dependent) diabetes mellitus. Br Med J (Clin Res Ed) 290:352-355, 1985
29. Smart LM, Howie AF, Young RJ, Walker SW, Clarke BF, Smith AF: Comparison of fructosamine with glycosylated hemoglobin and plasma proteins as measures of glycemic control. Diabetes Care 11:433-436, 1988
30. Dominiczak MH, Smith LA, McNaught J, Paterson KR: Assessment of past glycemie control: measure fructosamine, hemoglobin A1, or both? Diabetes Care 11:359-360, 1988
31. National Institutes of Health: Total prevalence of diabetes by race/ethnicity among people aged 20 years or older, United States, 2005 [article online]. Available from http://diabetes.niddk.nih.gov/dm/pubs/statistics/#10. Accessed 2 May 2007
32. Ziegler O, Kolopp M, Got I, Genton P, Debry G, Drouin P: Reliability of self-monitoring of blood glucose by CSII-treated patients with type I diabetes. Diabetes Care 12:184-188, 1989
33. Group DRiCNS: Accuracy of new-generation home blood glucose meters in a Diabetes Research in Children Network inpatient exercise study. Diabetes Technol Ther 7:675-680, 2005